Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has posted a promising update on its wholly-owned precision immunotherapy asset, bexmarilimab
In an open-label clinical trial, the clinical-stage biopharmaceutical company reported that a leukaemia patient with partial responses as communicated on October 31, achieved complete remission, with incomplete blood cell count recovery after four treatment cycles.
This was followed by full blood count recovery after five treatment cycles.
A second patient showed early signs of efficacy, with reduced blast counts in a similar pattern to the first patient.
The remaining patients of the first cohort have reported stable disease (SD) status.
The primary objective of the BEXMAB study is to determine the safety and tolerability of bexmarilimab in combination with standard-of-care (azacitidine and venetoclax) treatment and to identify the recommended Phase II dose.
In a statement, Dr Marie-Louise Fjällskog, Faron’s chief medical officer, said: “We continue to be encouraged by the promising early data observed in this trial, notably the patients who have already shown control of blast counts in blood and bone marrow.
"These observations support the potential for synergy of bexmarilimab in combination with standard of care. In addition, patient recruitment has started in the first-line triplet therapy with bexmarilimab, azacitidine and venetoclax in newly diagnosed acute myeloid leukaemia patients deemed unsuitable for conventional chemotherapy."